FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
Pauline Tétu(Inserm), Nicolas Dumaz(Inserm)
Cited by 9
Related Papers
Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients
|PLoS ONE|2018|112
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort
|European Journal of Cancer|2019|35
RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma
|Oncotarget|2015|33
RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy
|Biomedicines|2021|15
Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma
|European Journal of Cancer|2018|14